CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 171.48 AUD -2.38% Market Closed
Market Cap: 83.2B AUD

Intrinsic Value

The intrinsic value of one CSL stock under the Base Case scenario is 223.62 AUD. Compared to the current market price of 171.48 AUD, CSL Ltd is Undervalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CSL Intrinsic Value
223.62 AUD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
CSL Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about CSL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CSL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for CSL Ltd.

Explain Valuation
Compare CSL to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

CSL’s heavy dependence on plasma collection for its immunoglobulin and plasma-derived therapeutics creates a persistent risk of supply disruptions and higher costs, particularly in regions where donor compensation policies might shift.

Increasing competition from other plasma-focused companies such as Grifols and Takeda threatens CSL’s pricing power and could erode margins if rivals expand capacity or introduce new treatments more rapidly.

R&D efforts are capital-intensive and carry the potential for high-profile failures, which may slow CSL’s growth if pipeline projects like advanced gene therapies for rare diseases do not meet clinical or regulatory milestones.

Bull Theses

CSL’s global leadership in plasma-derived therapeutics and vaccines, supported by its extensive plasma-collection network, provides a durable competitive advantage and a reliable revenue base.

Continued success in new product launches, including next-generation gene therapies and high-demand influenza vaccines, has the potential to solidify CSL’s market position and diversify its earnings streams.

Strategic acquisitions such as Vifor Pharma, combined with ongoing investments in next-generation treatments, could unlock further synergies, bolster CSL’s portfolio in rare diseases, and strengthen its global market reach.

Show More Less
How do you feel about CSL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CSL Ltd

Current Assets 11.9B
Cash & Short-Term Investments 2.2B
Receivables 3.2B
Other Current Assets 6.5B
Non-Current Assets 27.6B
Long-Term Investments 203m
PP&E 9.8B
Intangibles 16.2B
Other Non-Current Assets 1.4B
Current Liabilities 4.8B
Accounts Payable 3.5B
Other Current Liabilities 1.4B
Non-Current Liabilities 15.3B
Long-Term Debt 10.7B
Other Non-Current Liabilities 4.6B
Efficiency

Free Cash Flow Analysis
CSL Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CSL Ltd

Revenue
15.6B USD
Cost of Revenue
-7.5B USD
Gross Profit
8.1B USD
Operating Expenses
-4B USD
Operating Income
4.1B USD
Other Expenses
-1.1B USD
Net Income
3B USD
Fundamental Scores

CSL Profitability Score
Profitability Due Diligence

CSL Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Healthy Operating Margin
Exceptional Gross Margin
Positive 3Y Average ROE
Sustainable 3Y Average Operating Margin
55/100
Profitability
Score

CSL Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

CSL Solvency Score
Solvency Due Diligence

CSL Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
63/100
Solvency
Score

CSL Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSL Price Targets Summary
CSL Ltd

Wall Street analysts forecast CSL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSL is 244.21 AUD with a low forecast of 189.88 AUD and a high forecast of 308.92 AUD.

Lowest
Price Target
189.88 AUD
11% Upside
Average
Price Target
244.21 AUD
42% Upside
Highest
Price Target
308.92 AUD
80% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CSL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

CSL News

Other Videos
What is the Intrinsic Value of one CSL stock?

The intrinsic value of one CSL stock under the Base Case scenario is 223.62 AUD.

Is CSL stock undervalued or overvalued?

Compared to the current market price of 171.48 AUD, CSL Ltd is Undervalued by 23%.

Back to Top